Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid.
| Company Name: |
Cognition Therapeutics Inc |
| Website: |
www.cogrx.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding CGTX: |
3 |
| Total Market Value Held by ETFs: |
$1.81M |
| Total Market Capitalization: |
$78.00M |
| % of Market Cap. Held by ETFs: |
2.32% |
|
|
April 27, 2024 • 6:34 PM Eastern
Strong Buy (4.00 out of 4)
95th percentile
|
|
Free CGTX Email Alerts:
